Actemra (Tocilizumab)
Actemra (Tocilizumab)
Regular price
₱0.00 PHP
Regular price
Sale price
₱0.00 PHP
Unit price
/
per
Rheumatoid arthritis, Giant Cell Arteritis and Cytokine Release Syndrome. Actemra may be used alone or with other medications.Actemra belongs to a class of drugs called DMARDs, Immunomodulators; Monoclonal Antibodies.
In clinical trials of hospitalized patients with COVID-19, Actemra in addition to the routine care patients receive for treatment of COVID-19, which included corticosteroid therapy, was shown to reduce the risk of death through 28 days of follow-up and decrease the amount of time patients remained hospitalizedIndication
- Rheumatoid arthritis
-
Giant Cell Arteritis (GCA)
-
Systemic Juvenile Idiopathic Arthritis (SJIA)
-
Polyarticular Juvenile Idiopathic Arthritis (PJIA)
-
Cytokine Release Syndrome (CRS)
The most common side effects of Actemra include:
- runny or stuffy nose,
- sinus pain,
- sore throat,
- headache,
- increased blood pressure,
- abnormal liver function tests, and
- pain, swelling, burning, or irritation where the injection was given
General Considerations For Administration
Avoid using ACTEMRA with biological DMARDs.
Storage and Stability
Do not use beyond expiration date on the container, package, prefilled syringe, or autoinjector. ACTEMRA must be refrigerated at 2°C to 8°C (36°F to 46°F). Do not freeze. Protect the vials, syringes, and autoinjectors from light by storage in the original package until time of use, and keep syringes and autoinjectors dry.
Philippne FDA Info | |
Registration Number | BR-689 |
Generic Name | Tocilizumab |
Brand Name | Actemra |
Dosage Strength | 400mg / 20 mL |
Dosage Form | Concentrate For Solution For I.V. Infusion |
Classification | Prescription Drug (RX) |
Packaging | 20 mL colorless Type I glass vial per box (box of 1's) |
Manufacturer | Chugai Pharma Manufacturing Co., Limited |
Country of Origin | Japan |
Trader | F. Hoffmann-La Roche Limited - Switzerland |
Importer | Roche (Philippines) Inc. |
Distributor | Zuellig Pharma Corporation |
Issuance Date | 18 June 2018 |
Expiry Date | 20 March 2023 |